
Y-mAbs Therapeutics Inc
NASDAQ:YMAB

Intrinsic Value
The intrinsic value of one
YMAB
stock under the Base Case scenario is
9.99
USD.
Compared to the current market price of 4.41 USD,
Y-mAbs Therapeutics Inc
is
Undervalued by 56%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Y-mAbs Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Y-mAbs Therapeutics Inc
Balance Sheet Decomposition
Y-mAbs Therapeutics Inc
Current Assets | 90.4m |
Cash & Short-Term Investments | 60.3m |
Receivables | 17.7m |
Other Current Assets | 12.4m |
Non-Current Assets | 22.2m |
PP&E | 762k |
Intangibles | 2.2m |
Other Non-Current Assets | 19.2m |
Free Cash Flow Analysis
Y-mAbs Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Y-mAbs Therapeutics Inc
Revenue
|
88.7m
USD
|
Cost of Revenue
|
-15.9m
USD
|
Gross Profit
|
72.8m
USD
|
Operating Expenses
|
-103.6m
USD
|
Operating Income
|
-30.8m
USD
|
Other Expenses
|
2.6m
USD
|
Net Income
|
-28.2m
USD
|
YMAB Profitability Score
Profitability Due Diligence
Y-mAbs Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Score
Y-mAbs Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
YMAB Solvency Score
Solvency Due Diligence
Y-mAbs Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Score
Y-mAbs Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
YMAB Price Targets Summary
Y-mAbs Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
YMAB
is 16.13 USD
with a low forecast of 3.03 USD and a high forecast of 27.3 USD.
Dividends
Current shareholder yield for YMAB is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
YMAB
stock under the Base Case scenario is
9.99
USD.
Compared to the current market price of 4.41 USD,
Y-mAbs Therapeutics Inc
is
Undervalued by 56%.